Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Other Operating Expenses (2020 - 2023)

Historic Other Operating Expenses for Ovid Therapeutics (OVID) over the last 4 years, with Q1 2023 value amounting to -$1000.0.

  • Ovid Therapeutics' Other Operating Expenses fell 10047.84% to -$1000.0 in Q1 2023 from the same period last year, while for Dec 2023 it was -$1000.0, marking a year-over-year decrease of 10013.14%. This contributed to the annual value of -$45690.0 for FY2021, which is 11155.54% down from last year.
  • As of Q1 2023, Ovid Therapeutics' Other Operating Expenses stood at -$1000.0, which was down 10047.84% from $836085.0 recorded in Q3 2022.
  • In the past 5 years, Ovid Therapeutics' Other Operating Expenses ranged from a high of $836085.0 in Q3 2022 and a low of -$438260.0 during Q4 2020
  • Its 4-year average for Other Operating Expenses is $92476.6, with a median of $828.5 in 2021.
  • Data for Ovid Therapeutics' Other Operating Expenses shows a peak YoY increase of 3136725.63% (in 2022) and a maximum YoY decrease of 1118831.94% (in 2022) over the last 5 years.
  • Over the past 4 years, Ovid Therapeutics' Other Operating Expenses (Quarter) stood at -$438260.0 in 2020, then skyrocketed by 100.89% to $3903.0 in 2021, then surged by 21321.6% to $836085.0 in 2022, then plummeted by 100.12% to -$1000.0 in 2023.
  • Its last three reported values are -$1000.0 in Q1 2023, $836085.0 for Q3 2022, and -$284127.0 during Q2 2022.